Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interaction of molecules in order to generate novel therapeutics.
We focus on how molecular interaction analysis and structural information can improve and advance the development of high quality, small molecule drug leads. This is combined with extensive expertise in fragment-based drug development from years of work in the pharmaceutical industry.
Today, the Company offers services and partnerships using the proprietary Sprint™ platform. This platform comprises state of the art Biacore surface plasmon resonance (SPR) equipment, proprietary analytical tools and a fragment library, paired with experienced people that truly understand the drug discovery process.
As well as providing services and building collaborations with external companies, Beactica is progressing its own drug discovery programmes.
Beactica AB is a privately held company founded in 2006 by Per Källblad, Ph.D., previously at Medivir AB, and Prof. Helena Danielson at Uppsala University. The company is based in Uppsala, Sweden and has received funding from the Swedish Governmental Agency for Innovation Systems (VINNNOVA), Uppsala University Holding Company, Innovationsbron Uppsala AB and ALMI Företagspartner.
If you are interested in Beactica – whether you’re a potential client, investor or employee – we’ll always be delighted to hear from you.
